https://bio.nikkeibp.co.jp/atcl/news/p1/24/07/10/12134/

Cyfuse and Iwatani Corporation announced on July 10, 2024 that they have developed a technology that can freeze three-dimensionally organized regenerative medicine products, which Cyfuse is developing, with liquid nitrogen.

Cyfuse uses “bio 3D printing” technology, which stacks spheroids three-dimensionally using a 3D printer. Currently, they are developing three types of autologous regenerative medicine products for the treatment of peripheral nerves, bone cartilage, and blood vessels. The regenerative medicine products for treating peripheral nerves target peripheral nerve damage and are made by using a bio 3D printer to create tubular “cell-made nerve conduits” from patient-derived fibroblasts. To date, investigator-initiated clinical trials have been completed.

The company and Iwatani have now developed a technology to freeze and store such three-dimensionally organized regenerative medicine products. The freezing technology uses liquid nitrogen, but details have not been disclosed. According to both companies this procedure is expected to greatly expand the options for manufacturing and storing 3D cell products in the future.